David Hallal was appointed Chairman of iTeos Therapeutics in June 2018. He also currently serves as the Chairman of Scholar Rock (Nasdaq: SRRK) and is an independent director of Seer Biosciences.
David has 30 years of experience in the biopharmaceutical industry including over 10 years at Alexion Pharmaceuticals where he played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenue by 2016. As CEO of Alexion, David transitioned the company from a single-product to a multi-product enterprise. This included the US, EU, and Japan approval and the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidate from a preclinical stage to registration trials in multiple diseases in just 18 months.
Prior to his appointment as CEO, David served as Alexion’s Chief Operating Officer and then Chief Commercial Officer, where he built the company’s commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team. Prior to Biogen, David also held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta® and Aranesp®. David holds a BA in Psychology from the University of New Hampshire.
What is David Hallal's net worth?
The estimated net worth of David Hallal is at least $1.49 million as of October 19th, 2022. Mr. Hallal owns 138,153 shares of iTeos Therapeutics stock worth more than $1,492,052 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Hallal may own. Learn More about David Hallal's net worth.
How do I contact David Hallal?
Has David Hallal been buying or selling shares of iTeos Therapeutics?
David Hallal has not been actively trading shares of iTeos Therapeutics during the last quarter. Most recently, David Hallal sold 1,171 shares of the business's stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $19.51, for a transaction totalling $22,846.21. Learn More on David Hallal's trading history.
Who are iTeos Therapeutics' active insiders?
Are insiders buying or selling shares of iTeos Therapeutics?
During the last year, iTeos Therapeutics insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $41,850.00. During the last year, insiders at the sold shares 1 times. They sold a total of 350,000 shares worth more than $5,691,000.00. The most recent insider tranaction occured on October, 12th when CFO Matthew Gall bought 5,000 shares worth more than $41,850.00. Insiders at iTeos Therapeutics own 10.2% of the company.
Learn More about insider trades at iTeos Therapeutics. Information on this page was last updated on 10/12/2023.
